Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.

http://www.wikidata.org/entity/Q35609611

about

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease Combination therapies: The next logical Step for the treatment of synucleinopathies?Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy.Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy Therapeutic approaches in Parkinson's disease and related disorders.The neuropathology of multiple system atrophy and its therapeutic implications.Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization.Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention

P2860

Q36265332-2A475D4E-FA5D-458F-BA67-63016B471B6D Q36383985-5A4070F4-1FFF-4A80-8DEA-0C82C2B75D4A Q36563062-03A5AB7A-D521-4565-B202-84FB788C33D3 Q36577891-32ED5FCE-5B54-4F2B-8176-AD11662F6F49 Q36672116-362D1705-7AD1-4811-9648-B7AB552DA359 Q37565960-D90FEAB1-8A27-4A2D-93E4-0F5DD753D08B Q38691406-6B663C1F-91EC-4AB3-B892-387560D6BF61 Q45940520-03177B82-F90D-47F1-B503-04D3C7E223DD Q52694955-429C6023-9E88-4752-B2BC-286208D784B7 Q58775998-95F7E3D9-1A31-4C1C-8687-D7F21E6F00DE Q58799080-7718CA3F-6913-4BDF-A351-8E908043F35E

P2860

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.

http://www.wikidata.org/entity/Q35609611

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Lenalidomide reduces microglia ...... model of Parkinson's disease.

@ast

Lenalidomide reduces microglia ...... model of Parkinson's disease.

@en

type

label

Lenalidomide reduces microglia ...... model of Parkinson's disease.

@ast

Lenalidomide reduces microglia ...... model of Parkinson's disease.

@en

prefLabel

Lenalidomide reduces microglia ...... model of Parkinson's disease.

@ast

Lenalidomide reduces microglia ...... model of Parkinson's disease.

@en

P1433

Q35609611-950D24D7-9F89-46FE-9AAF-B79EB85F5667

P1476

Q35609611-0B481CF5-B226-4B41-BC2C-2E9CCA93F406

P2093

Q35609611-1E288CE6-C6C4-41E7-A344-11BD4E34DE6A

Q35609611-6B643769-7A28-4C14-B61C-175B34B0207E

Q35609611-869522E9-844F-4681-9777-0FAC592FF81A

P2860

Q35609611-06D15EC7-8AB9-406B-972A-BAAB9F446C06

Q35609611-0B70381D-279D-4C08-B5E7-2E5A91A7977B

Q35609611-1101DD21-2936-4AD0-A92B-AB2E2478FB0B

Q35609611-18D69AA3-F34A-440F-9663-74274D2E4BBE

Q35609611-1E67B95A-7511-4F7B-9198-6D80132B0979

Q35609611-20D8C0A7-80F5-4549-86EC-9BA7C949FF94

Q35609611-232542D4-8E6F-4F0F-AD91-DC68D0923516

Q35609611-25E557F4-902A-444C-9F2D-06A2EB48098E

Q35609611-2F4A491E-7CA1-4D1F-8244-BDA352E57303

Q35609611-3056B3A3-F20B-4DE2-B0F5-5DF5B7179ABF

P2888

Q35609611-34DA1435-8D78-43C0-AA1E-79B3DDA71E34

P304

Q35609611-2B6E1EDC-B747-4CA1-9426-06FE260FFAD0

P31

Q35609611-7B321994-2D16-40BE-BC61-F62723975C6C

P356

Q35609611-E7BD028C-96E0-4AFE-A220-536984947F98

P478

Q35609611-29C4B1D4-2F9F-448C-9B4B-7DE7BD60044C

P50

Q35609611-6F7E6C39-EA18-4FDA-8F07-797D1CCB6AA8

Q35609611-7D29F2A8-C794-4BB2-8FDD-4C65FA5AA55C

P577

Q35609611-DCF60C90-3B0C-4441-82BA-B4AC08B5479A

P5875

Q35609611-5AF6A674-78F5-48F2-91C1-F891BFF31E6E

P6179

Q35609611-BA3BCCC9-024E-491D-9BD6-07B11E859A04

P698

Q35609611-37201BA2-9DB2-4A5B-9ED9-8229E7699609

P921

Q35609611-CD94954A-EBE7-4074-B383-8D03D56344AB

P932

Q35609611-EF5FDF86-06A1-465F-85AD-CAD703CABFC0

P356

S12974-015-0320-X

P1433

Journal of Neuroinflammation

P1476

Lenalidomide reduces microglia ...... model of Parkinson's disease.

@en

P2093

Elvira Valera

http://www.w3.org/2001/XMLSchema#string

Michael Mante

http://www.w3.org/2001/XMLSchema#string

Scott Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma

Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies

Use of ibuprofen and risk of Parkinson disease

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice

The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?

Alpha-synuclein in Lewy bodies

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy

P2888

s12974-015-0320-x

P304

93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12974-015-0320-X

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

Edward Rockenstein

P577

2015-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276355835

http://www.w3.org/2001/XMLSchema#string

P6179

1033450349

http://www.w3.org/2001/XMLSchema#string

P698

25966683

http://www.w3.org/2001/XMLSchema#string

P921

P932

4432827

http://www.w3.org/2001/XMLSchema#string